procaspase-3

Duocarmycin A, an antitumor antibiotic, is a DNA alkylator and efficiently alkylates adenine N3 at the 3′ end of AT-rich sequences in the DNA. Duocarmycin A, as a chemotherapeutic agent, results in HLC-2 cells typically apoptotic changes.

PAC-1 (Procaspase activating compound 1) has been used in trials studying the treatment of Lymphoma, Melanoma, Solid Tumors, Breast Cancer, and Thoracic Cancers, among others.

Procaspase-3 activator 1 is a potent activator of procaspase-3. It directly activates procaspase-3 through zinc chelation, inducing apoptosis and inhibiting cancer cell proliferation. Procaspase-3 activator 1 is applicable in research on non-small cell lung cancer (NSCLC) and melanoma.

17-Hydroxy sprengerinin C is a glycoside compound isolated from rhizomes of Polygonatum sibiricum with stronger anticancer activities. 17-Hydroxy sprengerinin C reduces the expression of Blc-2 and pro-caspase3 and increases the production of Bax.

CASP3 Activator 1541 is an activator of the proenzyme forms of caspase-3, and induces cell death.

Lb54 is an activator of caspase-3 and caspase-7 with an EC50 of 660.9 nM for human procaspase-3. It activates caspase-3/7, which cleaves Gasdermin D (GSDMD) at the aspartic acid residue 87 to produce a p10 fragment, thus preventing the formation of the pore-forming p30 fragment of GSDMD. By activating caspase-3/7, Lb54 inhibits GSDMD-mediated pyroptosis, thereby reducing inflammation and providing protection against sepsis. Additionally, Lb54 alleviates acute lung injury and suppresses systemic inflammation by inhibiting the maturation of monocyte-derived dendritic cells. Lb54 is applicable in sepsis-related research.

WF-210 is an effective activator of procaspase-3 that acts by inducing apoptosis in cancer cells and reducing tumor growth.

ZYZ-488 is an Apoptotic Protease-Activating Factor 1 (Apaf-1) inhibitor that inhibits the activation of procaspase-9 and procaspase-3. It can be used to study cardiovascular diseases.

MPT0B206 is a novel tubulin polymerization inhibitor. MPT0B206 induced G2/M cell cycle arrest and the appearance of the mitotic marker MPM-2 in K562 and K562R cells, which is associated with the upregulation of cyclin B1 and the dephosphorylation of Cdc2.